- Home
- BSM vs NRIX Comparison
BSM vs NRIX Comparison
Compare BSM & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSM | NRIX |
|---|---|---|
| Founded | 1876 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BSM | NRIX |
|---|---|---|
| Price | $15.16 | $24.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $14.00 | ★ $30.50 |
| AVG Volume (30 Days) | 292.8K | ★ 1.0M |
| Earning Date | 05-04-2026 | 04-08-2026 |
| Dividend Yield | ★ 8.40% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $469,919,000.00 | $76,987,000.00 |
| Revenue This Year | $11.03 | N/A |
| Revenue Next Year | $9.63 | $48.05 |
| P/E Ratio | $12.82 | ★ N/A |
| Revenue Growth | 8.35 | ★ 99.31 |
| 52 Week Low | $12.32 | $8.20 |
| 52 Week High | $15.49 | $28.23 |
Technical Indicators
Market Signals| Indicator | BSM | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 55.19 | 48.62 |
| Support Level | $14.53 | $24.95 |
| Resistance Level | $15.20 | $28.23 |
| Average True Range (ATR) | 0.23 | 1.05 |
| MACD | -0.00 | -0.24 |
| Stochastic Oscillator | 61.90 | 22.50 |
Price Performance
Historical ComparisonAbout BSM Black Stone Minerals L.P.
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests. The company owns mineral interests in approximately 16.9 million gross acres.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.